September 13, 2021 4:50pm

As provided this a.m., Regenxbio stock rocketed today after announcing an AbbVie eye-disease deal. At one point, RGNX (+$10.32 or +31.20%) stock hit a seven (7) month high

The Biostage (BSTG) Chronicles: The “pump/promote” was in full affect, Monday closed up +$0.04 to $3.83 with 26,150 shares – who or which entity is buying … all … these shares?

Pre-open indications: 1 HIT and 4 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.


The Dow closed UP +261.91 points (+0.76%); the S&P closed UP +10.15 points (+0.23%) while the Nasdaq closed DOWN -9.91 points (-0.07%)

 

Henry’omics:

Indexes were up except the Nasdaq which slipped down.

Stocks have been under pressure since August’s jobs report, released by the Labor Department on September 3, missed expectations.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened negative at 10/22, 2 flats and 1 acquired, flipped positive at the mid-day at 19/15 and 1 acquired, ending with a negative close of 15/19 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “the stem, cell and gene therapy sectors still vulnerable. Future uncertainty suggests volatility continuity and some temporary lasting upside.” …  https://www.regmedinvestors.com/articles/12091

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metric - volume:

  • Sector volume was LOW with 8 of the 15-upside having higher than the 3-month average volume with very LOW volume of 4 of 19-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: The usual “pump/promote”, Monday closed up +$0.04 to $3.83 with 26,150 shares traded following Fridays closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded after Wednesday traded +$0.57 with 7,833 shares traded, Tuesday closed down -$0.75 to $2.75 with 6,705 shares traded following Monday’s holiday

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?
  • Is management responding to U.S./non-U.S./ Chinese investors complaints after the last (listed pricing) private placement of $4.71?
  • Where are the monies coming from?

 

Pre-open Indications: 1 HIT < Regenxbio (RGNX +$10.32)> 4 MISS < Maintaining SELL: Biostage (BSTG +$0.01), Intellia Therapeutics (NTLA -$6.35), CRISPR Therapeutics (CRSP -$2.74), Editas Medicine (EDIT -$3.14)>

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Regenxbio (RGNX), Vericel (VCEL), bluebird bio (BLUE), Ionis Pharmaceuticals (IONS), Mesoblast (MESO) - again to name 5 of the 15 inclining of the 35 covered

Hammered in today’s market:

  • MiMedx (MDXG), Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY), ReNeuron (RENE), Editas Medicine (EDIT), to name 5 of the 19 declining of the 35 covered

Closing: Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -1.68% and XBI closed down -0.49%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -1.58 points or -7.54% at 19.37

 

September, the third month of Q3/21:

Monday (9/13) closed negative with 15 advancers, 19 decliners and 1 acquired

 

The BOTTOM LINE: Maintaining my position, I haven’t had long to wait for a bumpy September-October timeframe.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.